Plc Systems Inc: (OTC: PLCSF)

$0.14

-0.01 (-9.03%)

Volume 251,130

May 17 03:53 PM ET

Zacks Rank: 3-Hold

 
 
#3
 
 

Overview Quote

Get Overview Quote for:

Stock Activity

Day Low - High 0.14 - 0.15
52wk Low - High 0.11 - 0.30
Previous Close 0.15
Avg. Volume 362,177
Industry MED PRODUCTS
Market Cap 7.66 M
Div - Yield 0.00 - 0.00
Beta 1.63
PE (Forward) 0.00
Current Year Est. -0.10
Quarterly Earnings ESP NA

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

Rank Change Trend3

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

NA

Zacks Industry Rank

175 out of 265

Equity Research Report

Updated as of NA

PREMIUM

( = Change in last 30 days)

Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial

Key Earnings Data

PE (Forward) NA
PEG Ratio NA
Current Year Est. -0.10
Current Quarter Estimate -0.03
Most Accurate Estimate NA
Earnings ESP NA
Next Earnings Report Date 05-16-2013
EPS Last Year -0.02
Expected Earnings Growth NA

Company Description

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. The CO2 Heart Laser is the world's first TMR angina relief device approved by both the U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and Welfare. In a move to broaden its market, the company recently announced its intention to initiate clinical studies for its RenalGuard Therapy and RenalGuard System. RenalGuard Therapy is designed to reduce the toxic effects that contrast media can have on the kidneys. It is based on the theory that creating and maintaining a high urine output is beneficial to patients undergoing imaging procedures where contrast agents are used.

NYSE data is at least 20 minutes delayed.

NASDAQ data is at least 15 minutes delayed.

Interactive Java Charting | Fundamental Charts

Introducing Zacks Whisper Trader

Turn Earnings Surprises into quick profits.

 

PLCSF Chart by YCharts

Earnings Estimates

Current Qtr
(03/2013)
Next Qtr
(06/2013)
Current Year
(12/2013)
Next Year
(12/2014)
Average Estimate -0.03 -0.02 -0.10 -0.05
Number of Estimates 2 2 2 2
Low Estimate -0.03 -0.02 -0.11 -0.08
High Estimate -0.03 -0.02 -0.09 NA
Year Ago EPS -0.04 -0.04 -0.21 -0.10
EPS Growth 25.00% 50.00% 52.38% 45.00%

Average Earnings Estimates for PLCSF

EPS Growth for PLCSF

Industry Analysis

Name Symbol Previous Close Zacks Rank Zacks Recommendation
PLC SYSTEMS INC PLCSF 0.14
CONCEPTUS INC CPTS 30.92
ATRICURE INC ATRC 9.07
CYTOSORBENTS CP CTSO 0.12
INVIVO THERAPT NVIV 2.89
TRANS1 INC TSON 1.70
ABAXIS INC ABAX 45.35
ADVAXIS INC ADXS 0.05
ALERE INC ALR 26.30
BAXTER INTL BAX 72.94

Sector:Medical>> Industry:MED PRODUCTS

COMPARE TICKER vs. Its Peers

Financials

EPS TTM -0.02
Sales 1
Net Income -2
Price/Earnings NA
Price/Book NA
Price/Cash Flow NA
Price/Sales 7.09

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.